Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

Michel D. Wissing, Janet Mendonca, Madeleine S.Q. Kortenhorst, Nadine S. Kaelber, Matthew Gonzalez, Eunice Kim, Hans Hammers, Paul J. Van Diest, Michael A. Carducci, Sushant K. Kachhap

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Combinations of anticancer therapies with high efficacy and low toxicities are highly sought after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat. IC 50s of Plk1 inhibitors BI 2536 and BI 6727 were determined in prostate cancer cells by MTS assays. Morphological and molecular changes were assessed by immunoblotting, immunofluorescence, flow cytometry, real-time RT-PCR, and pulldown assays. Efficacy of combination therapy was assessed by MTS and clonogenic assays. IC50 values in DU 145, LNCaP, and PC3 cells were 50, 75, and 175 nM, respectively, for BI 2536 and 2. 5, 5, and 600 nM, respectively, for BI 6727. Human prostate fibroblasts and normal prostate epithelial cells were unaffected at these concentrations. While DU145 and LNCaP cells were solely arrested in mitosis on treatment, PC3 cells accumulated in G2 phase and mitosis, suggesting a weak spindle assembly checkpoint. Combining Plk1 inhibitors with HDAC inhibitors had synergistic antitumor effects in vitro. DMSO-treated prostate cancer cells were used as controls to study the effect of Plk1 and HDAC inhibition. Plk1 inhibitors decreased proliferation and clonogenic potential of prostate cancer cells. Hence, Plk1 may serve as an important molecular target for inhibiting prostate cancer. Combining HDAC inhibitors with BI 2536 or BI 6727 may be an effective treatment strategy against prostate cancer.

Original languageEnglish (US)
Pages (from-to)4279-4293
Number of pages15
JournalFASEB Journal
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Histone Deacetylase Inhibitors
Prostatic Neoplasms
Cells
Cell Line
Assays
Mitosis
Prostate
Histone Deacetylases
M Phase Cell Cycle Checkpoints
Flow cytometry
Valproic Acid
Fibroblasts
Dimethyl Sulfoxide
G2 Phase
Therapeutics
Toxicity
polo-like kinase 1
Immunoblotting
Inhibitory Concentration 50
Fluorescent Antibody Technique

Keywords

  • HDAC
  • Mitotic kinases
  • Plk1
  • Spindle assembly checkpoint
  • Synergy

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Wissing, M. D., Mendonca, J., Kortenhorst, M. S. Q., Kaelber, N. S., Gonzalez, M., Kim, E., ... Kachhap, S. K. (2013). Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB Journal, 27(10), 4279-4293. https://doi.org/10.1096/fj.12-222893

Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. / Wissing, Michel D.; Mendonca, Janet; Kortenhorst, Madeleine S.Q.; Kaelber, Nadine S.; Gonzalez, Matthew; Kim, Eunice; Hammers, Hans; Van Diest, Paul J.; Carducci, Michael A.; Kachhap, Sushant K.

In: FASEB Journal, Vol. 27, No. 10, 01.10.2013, p. 4279-4293.

Research output: Contribution to journalArticle

Wissing, MD, Mendonca, J, Kortenhorst, MSQ, Kaelber, NS, Gonzalez, M, Kim, E, Hammers, H, Van Diest, PJ, Carducci, MA & Kachhap, SK 2013, 'Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors', FASEB Journal, vol. 27, no. 10, pp. 4279-4293. https://doi.org/10.1096/fj.12-222893
Wissing, Michel D. ; Mendonca, Janet ; Kortenhorst, Madeleine S.Q. ; Kaelber, Nadine S. ; Gonzalez, Matthew ; Kim, Eunice ; Hammers, Hans ; Van Diest, Paul J. ; Carducci, Michael A. ; Kachhap, Sushant K. / Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. In: FASEB Journal. 2013 ; Vol. 27, No. 10. pp. 4279-4293.
@article{551bc5675e8a44a9bd2da6d792ba0d09,
title = "Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors",
abstract = "Combinations of anticancer therapies with high efficacy and low toxicities are highly sought after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat. IC 50s of Plk1 inhibitors BI 2536 and BI 6727 were determined in prostate cancer cells by MTS assays. Morphological and molecular changes were assessed by immunoblotting, immunofluorescence, flow cytometry, real-time RT-PCR, and pulldown assays. Efficacy of combination therapy was assessed by MTS and clonogenic assays. IC50 values in DU 145, LNCaP, and PC3 cells were 50, 75, and 175 nM, respectively, for BI 2536 and 2. 5, 5, and 600 nM, respectively, for BI 6727. Human prostate fibroblasts and normal prostate epithelial cells were unaffected at these concentrations. While DU145 and LNCaP cells were solely arrested in mitosis on treatment, PC3 cells accumulated in G2 phase and mitosis, suggesting a weak spindle assembly checkpoint. Combining Plk1 inhibitors with HDAC inhibitors had synergistic antitumor effects in vitro. DMSO-treated prostate cancer cells were used as controls to study the effect of Plk1 and HDAC inhibition. Plk1 inhibitors decreased proliferation and clonogenic potential of prostate cancer cells. Hence, Plk1 may serve as an important molecular target for inhibiting prostate cancer. Combining HDAC inhibitors with BI 2536 or BI 6727 may be an effective treatment strategy against prostate cancer.",
keywords = "HDAC, Mitotic kinases, Plk1, Spindle assembly checkpoint, Synergy",
author = "Wissing, {Michel D.} and Janet Mendonca and Kortenhorst, {Madeleine S.Q.} and Kaelber, {Nadine S.} and Matthew Gonzalez and Eunice Kim and Hans Hammers and {Van Diest}, {Paul J.} and Carducci, {Michael A.} and Kachhap, {Sushant K.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1096/fj.12-222893",
language = "English (US)",
volume = "27",
pages = "4279--4293",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "10",

}

TY - JOUR

T1 - Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

AU - Wissing, Michel D.

AU - Mendonca, Janet

AU - Kortenhorst, Madeleine S.Q.

AU - Kaelber, Nadine S.

AU - Gonzalez, Matthew

AU - Kim, Eunice

AU - Hammers, Hans

AU - Van Diest, Paul J.

AU - Carducci, Michael A.

AU - Kachhap, Sushant K.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Combinations of anticancer therapies with high efficacy and low toxicities are highly sought after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat. IC 50s of Plk1 inhibitors BI 2536 and BI 6727 were determined in prostate cancer cells by MTS assays. Morphological and molecular changes were assessed by immunoblotting, immunofluorescence, flow cytometry, real-time RT-PCR, and pulldown assays. Efficacy of combination therapy was assessed by MTS and clonogenic assays. IC50 values in DU 145, LNCaP, and PC3 cells were 50, 75, and 175 nM, respectively, for BI 2536 and 2. 5, 5, and 600 nM, respectively, for BI 6727. Human prostate fibroblasts and normal prostate epithelial cells were unaffected at these concentrations. While DU145 and LNCaP cells were solely arrested in mitosis on treatment, PC3 cells accumulated in G2 phase and mitosis, suggesting a weak spindle assembly checkpoint. Combining Plk1 inhibitors with HDAC inhibitors had synergistic antitumor effects in vitro. DMSO-treated prostate cancer cells were used as controls to study the effect of Plk1 and HDAC inhibition. Plk1 inhibitors decreased proliferation and clonogenic potential of prostate cancer cells. Hence, Plk1 may serve as an important molecular target for inhibiting prostate cancer. Combining HDAC inhibitors with BI 2536 or BI 6727 may be an effective treatment strategy against prostate cancer.

AB - Combinations of anticancer therapies with high efficacy and low toxicities are highly sought after. Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat. IC 50s of Plk1 inhibitors BI 2536 and BI 6727 were determined in prostate cancer cells by MTS assays. Morphological and molecular changes were assessed by immunoblotting, immunofluorescence, flow cytometry, real-time RT-PCR, and pulldown assays. Efficacy of combination therapy was assessed by MTS and clonogenic assays. IC50 values in DU 145, LNCaP, and PC3 cells were 50, 75, and 175 nM, respectively, for BI 2536 and 2. 5, 5, and 600 nM, respectively, for BI 6727. Human prostate fibroblasts and normal prostate epithelial cells were unaffected at these concentrations. While DU145 and LNCaP cells were solely arrested in mitosis on treatment, PC3 cells accumulated in G2 phase and mitosis, suggesting a weak spindle assembly checkpoint. Combining Plk1 inhibitors with HDAC inhibitors had synergistic antitumor effects in vitro. DMSO-treated prostate cancer cells were used as controls to study the effect of Plk1 and HDAC inhibition. Plk1 inhibitors decreased proliferation and clonogenic potential of prostate cancer cells. Hence, Plk1 may serve as an important molecular target for inhibiting prostate cancer. Combining HDAC inhibitors with BI 2536 or BI 6727 may be an effective treatment strategy against prostate cancer.

KW - HDAC

KW - Mitotic kinases

KW - Plk1

KW - Spindle assembly checkpoint

KW - Synergy

UR - http://www.scopus.com/inward/record.url?scp=84885146283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885146283&partnerID=8YFLogxK

U2 - 10.1096/fj.12-222893

DO - 10.1096/fj.12-222893

M3 - Article

VL - 27

SP - 4279

EP - 4293

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 10

ER -